Recent Updates
Recently added Catalysts
HRTX Positive Sentiment

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Key Takeaway: Heron Therapeutics, Inc. has announced that CEO Craig Collard will participate in a fireside chat during the 23rd Annual Needham Virtual Healthcare Conference, which takes place from April 8-11, 2024. The event will be accessible through a live webcast on the company's website. This participation underscores Heron's focus on therapeutic innovations aimed at enhancing patient care in healthcare and oncology.
Price reaction · baseline $2.74 (2024-03-27 close) · hit after-hours · clean, no other HRTX news in the window
day 0 close · peak
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Heron Therapeutics will present at a notable healthcare conference.
  • The participation highlights Heron's commitment to improving patient care.
  • A live webcast ensures accessibility for interested stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
9.9%
average across 6 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
HTX-011A
Phase 2 · Postoperative Pain

Full Press Release Details

SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.
A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.

Frequently Asked Questions

When will Craig Collard speak at the Needham Conference?

Craig Collard will speak on April 10, 2024, at 11:00 AM ET.

How can I watch the fireside chat?

The fireside chat will be streamed live on Heron's website.

What is the focus of Heron Therapeutics?

Heron Therapeutics focuses on developing therapies that enhance medical care.

What type of statements does Heron warn about?

Heron cautions about forward-looking statements that may change over time.

Where can I find more information about Heron?

More information is available on the company's website at www.herontx.com.

Last updated: Mar 28, 2024